カテゴリー： QYResearch, 世界

世界の糖尿病網膜症治療薬市場規模・現状・予測2021-2027

【英語タイトル】Global Diabetic Retinopathy Drugs Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料（QY21APR1838）・商品コード：QY21APR1838
・発行会社（調査会社）：QYResearch
・発行日：2021年4月
・ページ数：98
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥499,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥748,800見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,800 ⇒換算￥998,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
本調査資料では、糖尿病網膜症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ルセンティス、オプチナ、イルビエン、ベータメタゾン、オズルデックス、その他）、用途別市場規模（50〜60歳、60〜70歳、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・糖尿病網膜症治療薬の市場動向
・企業の競争状況、市場シェア
・糖尿病網膜症治療薬の種類別市場規模（ルセンティス、オプチナ、イルビエン、ベータメタゾン、オズルデックス、その他）
・糖尿病網膜症治療薬の用途別市場規模（50〜60歳、60〜70歳、その他）
・糖尿病網膜症治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・糖尿病網膜症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・糖尿病網膜症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・糖尿病網膜症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・糖尿病網膜症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan）
・結論
【レポートの概要】

Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.

Market Analysis and Insights: Global Diabetic Retinopathy Drugs Market
The global Diabetic Retinopathy Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Retinopathy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Retinopathy Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Retinopathy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Retinopathy Drugs market.

Global Diabetic Retinopathy Drugs Scope and Market Size
Diabetic Retinopathy Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Retinopathy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Lucentis
Optina
Iluvien
Betamethazone
Ozurdex
Other

Segment by Application
50-60 Years Old
60-70 Years Old
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Retinopathy Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lucentis
1.2.3 Optina
1.2.4 Iluvien
1.2.5 Betamethazone
1.2.6 Ozurdex
1.2.7 Other
1.3 Market by Application
1.3.1 Global Diabetic Retinopathy Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 50-60 Years Old
1.3.3 60-70 Years Old
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Diabetic Retinopathy Drugs Market Perspective (2016-2027)
2.2 Diabetic Retinopathy Drugs Growth Trends by Regions
2.2.1 Diabetic Retinopathy Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Diabetic Retinopathy Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Diabetic Retinopathy Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Diabetic Retinopathy Drugs Industry Dynamic
2.3.1 Diabetic Retinopathy Drugs Market Trends
2.3.2 Diabetic Retinopathy Drugs Market Drivers
2.3.3 Diabetic Retinopathy Drugs Market Challenges
2.3.4 Diabetic Retinopathy Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Diabetic Retinopathy Drugs Players by Revenue
3.1.1 Global Top Diabetic Retinopathy Drugs Players by Revenue (2016-2021)
3.1.2 Global Diabetic Retinopathy Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Diabetic Retinopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Retinopathy Drugs Revenue
3.4 Global Diabetic Retinopathy Drugs Market Concentration Ratio
3.4.1 Global Diabetic Retinopathy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy Drugs Revenue in 2020
3.5 Diabetic Retinopathy Drugs Key Players Head office and Area Served
3.6 Key Players Diabetic Retinopathy Drugs Product Solution and Service
3.7 Date of Enter into Diabetic Retinopathy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Diabetic Retinopathy Drugs Breakdown Data by Type
4.1 Global Diabetic Retinopathy Drugs Historic Market Size by Type (2016-2021)
4.2 Global Diabetic Retinopathy Drugs Forecasted Market Size by Type (2022-2027)

5 Diabetic Retinopathy Drugs Breakdown Data by Application
5.1 Global Diabetic Retinopathy Drugs Historic Market Size by Application (2016-2021)
5.2 Global Diabetic Retinopathy Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Diabetic Retinopathy Drugs Market Size (2016-2027)
6.2 North America Diabetic Retinopathy Drugs Market Size by Type
6.2.1 North America Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
6.2.2 North America Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
6.2.3 North America Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
6.3 North America Diabetic Retinopathy Drugs Market Size by Application
6.3.1 North America Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
6.3.2 North America Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
6.3.3 North America Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
6.4 North America Diabetic Retinopathy Drugs Market Size by Country
6.4.1 North America Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
6.4.2 North America Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Diabetic Retinopathy Drugs Market Size (2016-2027)
7.2 Europe Diabetic Retinopathy Drugs Market Size by Type
7.2.1 Europe Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
7.2.2 Europe Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
7.2.3 Europe Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
7.3 Europe Diabetic Retinopathy Drugs Market Size by Application
7.3.1 Europe Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
7.3.2 Europe Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
7.3.3 Europe Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
7.4 Europe Diabetic Retinopathy Drugs Market Size by Country
7.4.1 Europe Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
7.4.2 Europe Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size (2016-2027)
8.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type
8.2.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application
8.3.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region
8.4.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Diabetic Retinopathy Drugs Market Size (2016-2027)
9.2 Latin America Diabetic Retinopathy Drugs Market Size by Type
9.2.1 Latin America Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
9.3 Latin America Diabetic Retinopathy Drugs Market Size by Application
9.3.1 Latin America Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
9.4 Latin America Diabetic Retinopathy Drugs Market Size by Country
9.4.1 Latin America Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size (2016-2027)
10.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type
10.2.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application
10.3.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country
10.4.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Diabetic Retinopathy Drugs Introduction
11.1.4 Novartis Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Diabetic Retinopathy Drugs Introduction
11.2.4 Bayer Healthcare Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.2.5 Bayer Healthcare Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Diabetic Retinopathy Drugs Introduction
11.3.4 Roche Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Neurotech Pharmaceuticals
11.4.1 Neurotech Pharmaceuticals Company Details
11.4.2 Neurotech Pharmaceuticals Business Overview
11.4.3 Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Introduction
11.4.4 Neurotech Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.4.5 Neurotech Pharmaceuticals Recent Development
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Details
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.5.5 Regeneron Pharmaceuticals Recent Development
11.6 Allergan
11.6.1 Allergan Company Details
11.6.2 Allergan Business Overview
11.6.3 Allergan Diabetic Retinopathy Drugs Introduction
11.6.4 Allergan Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.6.5 Allergan Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Diabetic Retinopathy Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lucentis
Table 3. Key Players of Optina
Table 4. Key Players of Iluvien
Table 5. Key Players of Betamethazone
Table 6. Key Players of Ozurdex
Table 7. Key Players of Other
Table 8. Global Diabetic Retinopathy Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Diabetic Retinopathy Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Diabetic Retinopathy Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Diabetic Retinopathy Drugs Market Share by Regions (2016-2021)
Table 12. Global Diabetic Retinopathy Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Diabetic Retinopathy Drugs Market Share by Regions (2022-2027)
Table 14. Diabetic Retinopathy Drugs Market Trends
Table 15. Diabetic Retinopathy Drugs Market Drivers
Table 16. Diabetic Retinopathy Drugs Market Challenges
Table 17. Diabetic Retinopathy Drugs Market Restraints
Table 18. Global Diabetic Retinopathy Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Diabetic Retinopathy Drugs Market Share by Players (2016-2021)
Table 20. Global Top Diabetic Retinopathy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Retinopathy Drugs as of 2020)
Table 21. Ranking of Global Top Diabetic Retinopathy Drugs Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Diabetic Retinopathy Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Diabetic Retinopathy Drugs Product Solution and Service
Table 25. Date of Enter into Diabetic Retinopathy Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Diabetic Retinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2016-2021)
Table 29. Global Diabetic Retinopathy Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Diabetic Retinopathy Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Diabetic Retinopathy Drugs Revenue Market Share by Application (2016-2021)
Table 33. Global Diabetic Retinopathy Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Diabetic Retinopathy Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Diabetic Retinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Diabetic Retinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Diabetic Retinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Diabetic Retinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Diabetic Retinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Diabetic Retinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Diabetic Retinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Diabetic Retinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Diabetic Retinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Diabetic Retinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Diabetic Retinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Diabetic Retinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Diabetic Retinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Diabetic Retinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Diabetic Retinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Diabetic Retinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Diabetic Retinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Diabetic Retinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 65. Novartis Company Details
Table 66. Novartis Business Overview
Table 67. Novartis Diabetic Retinopathy Drugs Product
Table 68. Novartis Revenue in Diabetic Retinopathy Drugs Business (2016-2021) & (US$ Million)
Table 69. Novartis Recent Development
Table 70. Bayer Healthcare Company Details
Table 71. Bayer Healthcare Business Overview
Table 72. Bayer Healthcare Diabetic Retinopathy Drugs Product
Table 73. Bayer Healthcare Revenue in Diabetic Retinopathy Drugs Business (2016-2021) & (US$ Million)
Table 74. Bayer Healthcare Recent Development
Table 75. Roche Company Details
Table 76. Roche Business Overview
Table 77. Roche Diabetic Retinopathy Drugs Product
Table 78. Roche Revenue in Diabetic Retinopathy Drugs Business (2016-2021) & (US$ Million)
Table 79. Roche Recent Development
Table 80. Neurotech Pharmaceuticals Company Details
Table 81. Neurotech Pharmaceuticals Business Overview
Table 82. Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Product
Table 83. Neurotech Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2016-2021) & (US$ Million)
Table 84. Neurotech Pharmaceuticals Recent Development
Table 85. Regeneron Pharmaceuticals Company Details
Table 86. Regeneron Pharmaceuticals Business Overview
Table 87. Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Product
Table 88. Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2016-2021) & (US$ Million)
Table 89. Regeneron Pharmaceuticals Recent Development
Table 90. Allergan Company Details
Table 91. Allergan Business Overview
Table 92. Allergan Diabetic Retinopathy Drugs Product
Table 93. Allergan Revenue in Diabetic Retinopathy Drugs Business (2016-2021) & (US$ Million)
Table 94. Allergan Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Retinopathy Drugs Market Share by Type: 2020 VS 2027
Figure 2. Lucentis Features
Figure 3. Optina Features
Figure 4. Iluvien Features
Figure 5. Betamethazone Features
Figure 6. Ozurdex Features
Figure 7. Other Features
Figure 8. Global Diabetic Retinopathy Drugs Market Share by Application: 2020 VS 2027
Figure 9. 50-60 Years Old Case Studies
Figure 10. 60-70 Years Old Case Studies
Figure 11. Other Case Studies
Figure 12. Diabetic Retinopathy Drugs Report Years Considered
Figure 13. Global Diabetic Retinopathy Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Diabetic Retinopathy Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Diabetic Retinopathy Drugs Market Share by Regions: 2020 VS 2027
Figure 16. Global Diabetic Retinopathy Drugs Market Share by Regions (2022-2027)
Figure 17. Global Diabetic Retinopathy Drugs Market Share by Players in 2020
Figure 18. Global Top Diabetic Retinopathy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Retinopathy Drugs as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Diabetic Retinopathy Drugs Revenue in 2020
Figure 20. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2016-2021)
Figure 21. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2022-2027)
Figure 22. North America Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Diabetic Retinopathy Drugs Market Share by Type (2016-2027)
Figure 24. North America Diabetic Retinopathy Drugs Market Share by Application (2016-2027)
Figure 25. North America Diabetic Retinopathy Drugs Market Share by Country (2016-2027)
Figure 26. United States Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Diabetic Retinopathy Drugs Market Share by Type (2016-2027)
Figure 30. Europe Diabetic Retinopathy Drugs Market Share by Application (2016-2027)
Figure 31. Europe Diabetic Retinopathy Drugs Market Share by Country (2016-2027)
Figure 32. Germany Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Diabetic Retinopathy Drugs Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Diabetic Retinopathy Drugs Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Diabetic Retinopathy Drugs Market Share by Region (2016-2027)
Figure 42. China Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Diabetic Retinopathy Drugs Market Share by Type (2016-2027)
Figure 50. Latin America Diabetic Retinopathy Drugs Market Share by Application (2016-2027)
Figure 51. Latin America Diabetic Retinopathy Drugs Market Share by Country (2016-2027)
Figure 52. Mexico Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Diabetic Retinopathy Drugs Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Diabetic Retinopathy Drugs Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Diabetic Retinopathy Drugs Market Share by Country (2016-2027)
Figure 58. Turkey Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Diabetic Retinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Novartis Revenue Growth Rate in Diabetic Retinopathy Drugs Business (2016-2021)
Figure 62. Bayer Healthcare Revenue Growth Rate in Diabetic Retinopathy Drugs Business (2016-2021)
Figure 63. Roche Revenue Growth Rate in Diabetic Retinopathy Drugs Business (2016-2021)
Figure 64. Neurotech Pharmaceuticals Revenue Growth Rate in Diabetic Retinopathy Drugs Business (2016-2021)
Figure 65. Regeneron Pharmaceuticals Revenue Growth Rate in Diabetic Retinopathy Drugs Business (2016-2021)
Figure 66. Allergan Revenue Growth Rate in Diabetic Retinopathy Drugs Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed


【掲載企業】

Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan

★調査レポート[世界の糖尿病網膜症治療薬市場規模・現状・予測2021-2027] (コード：QY21APR1838)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の糖尿病網膜症治療薬市場規模・現状・予測2021-2027]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場規模・現状・予測2021-2027
    QY21APR3523 / QYResearch / 2021年4月 / 本調査資料では、黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（黄斑変性症治療薬、糖尿病性網膜症治療薬）、用途別市場規模（50〜60歳、60〜70歳、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の市場動向 ・企業の競争状況、市場シェア ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の種類別市場規模（黄斑変性症治療薬、糖尿病性網膜症治療薬） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の用途別市場規模（50〜60歳、60〜70歳、その他） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）...Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes. The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period. Market Analysis and Insights: Global Macular Degeneration (AMD) and...
  • 世界の糖尿病網膜症市場規模・現状・予測2021-2027
    QY21APR1839 / QYResearch / 2021年4月 / 本調査資料では、糖尿病網膜症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（レーザー手術、コルチコステロイド注射、抗VEGF薬、硝子体切除術）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病網膜症の市場動向 ・企業の競争状況、市場シェア ・糖尿病網膜症の種類別市場規模（レーザー手術、コルチコステロイド注射、抗VEGF薬、硝子体切除術） ・糖尿病網膜症の用途別市場規模（病院、クリニック、その他） ・糖尿病網膜症の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病網膜症の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病網膜症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病網膜症の中南米市場規模2016-2027（メキシコ、ブラジル）...Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are...
  • 世界の増殖性糖尿病性網膜症市場規模・現状・予測2021-2027
    QY21APR4819 / QYResearch / 2021年4月 / 本調査資料では、増殖性糖尿病性網膜症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗VEGF剤、コルチコステロイド）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・増殖性糖尿病性網膜症の市場動向 ・企業の競争状況、市場シェア ・増殖性糖尿病性網膜症の種類別市場規模（抗VEGF剤、コルチコステロイド） ・増殖性糖尿病性網膜症の用途別市場規模（病院、診療所、その他） ・増殖性糖尿病性網膜症の北米市場規模2016-2027（アメリカ、カナダ） ・増殖性糖尿病性網膜症の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・増殖性糖尿病性網膜症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・増殖性糖尿病性網膜症の中南米市場規模2016-2027（メキシコ、ブラジル）...Market Analysis and Insights: Global Proliferative Diabetic Retinopathy Market The global Proliferative Diabetic Retinopathy market size is projected to reach US$ 624.2 million by 2026, from US$ 430.5 million in 2019, at a CAGR of 5.4% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Proliferative Diabetic Retinopathy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Proliferative Diabetic Retinopathy market in terms...
  • 世界の糖尿病網膜症治療市場規模・現状・予測2021-2027
    QY21APR1840 / QYResearch / 2021年4月 / 本調査資料では、糖尿病網膜症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（増殖性糖尿病性網膜症（PDR）、非増殖性糖尿病性網膜症（NPDR））、用途別市場規模（眼科クリニック、外来手術センター、病院、その他エンドユーザー）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病網膜症治療の市場動向 ・企業の競争状況、市場シェア ・糖尿病網膜症治療の種類別市場規模（増殖性糖尿病性網膜症（PDR）、非増殖性糖尿病性網膜症（NPDR）） ・糖尿病網膜症治療の用途別市場規模（眼科クリニック、外来手術センター、病院、その他エンドユーザー） ・糖尿病網膜症治療の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病網膜症治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病網膜症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病網膜症治療の中南米市場規模2016-2027（メキシコ、ブラジル）...Diabetic retinopathy (die-uh-BET-ik ret-ih-NOP-uh-thee) is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Market Analysis and Insights: Global Diabetic Retinopathy Treatment Market The global Diabetic Retinopathy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Retinopathy Treatment market to help players in achieving...
  • 世界の糖尿病性胃不全麻痺治療薬市場規模・現状・予測2021-2027
    QY21APR1830 / QYResearch / 2021年4月 / 本調査資料では、糖尿病性胃不全麻痺治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（運動促進剤、制吐剤、その他）、用途別市場規模（病院薬局、民間クリニック、ドラッグストア、Eコマース）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病性胃不全麻痺治療薬の市場動向 ・企業の競争状況、市場シェア ・糖尿病性胃不全麻痺治療薬の種類別市場規模（運動促進剤、制吐剤、その他） ・糖尿病性胃不全麻痺治療薬の用途別市場規模（病院薬局、民間クリニック、ドラッグストア、Eコマース） ・糖尿病性胃不全麻痺治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病性胃不全麻痺治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病性胃不全麻痺治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病性胃不全麻痺治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）...Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes. Market Analysis and Insights: Global Diabetic Gastroparesis Drugs Market The global Diabetic Gastroparesis Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Gastroparesis Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those...
  • 世界の抗糖尿病薬市場規模・現状・予測2021-2027
    QY21APR0381 / QYResearch / 2021年4月 / 本調査資料では、抗糖尿病薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ビグアニド、スルホニル尿素、メグリチニド、チアゾリジンジオン、ジペプチジルペプチダーゼIV阻害剤、α-グルコシダーゼ阻害剤）、用途別市場規模（I型糖尿病、II型糖尿病、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・抗糖尿病薬の市場動向 ・企業の競争状況、市場シェア ・抗糖尿病薬の種類別市場規模（ビグアニド、スルホニル尿素、メグリチニド、チアゾリジンジオン、ジペプチジルペプチダーゼIV阻害剤、α-グルコシダーゼ阻害剤） ・抗糖尿病薬の用途別市場規模（I型糖尿病、II型糖尿病、その他） ・抗糖尿病薬の北米市場規模2016-2027（アメリカ、カナダ） ・抗糖尿病薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗糖尿病薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗糖尿病薬の中南米市場規模2016-2027（メキシコ、ブラジル）...The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally. Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages...
  • 世界の糖尿病性胃不全麻痺治療市場規模・現状・予測2021-2027
    QY21APR1831 / QYResearch / 2021年4月 / 本調査資料では、糖尿病性胃不全麻痺治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、手術治療製品）、用途別市場規模（病院薬局、民間クリニック、ドラッグストア、Eコマース）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病性胃不全麻痺治療の市場動向 ・企業の競争状況、市場シェア ・糖尿病性胃不全麻痺治療の種類別市場規模（医薬品、手術治療製品） ・糖尿病性胃不全麻痺治療の用途別市場規模（病院薬局、民間クリニック、ドラッグストア、Eコマース） ・糖尿病性胃不全麻痺治療の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病性胃不全麻痺治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病性胃不全麻痺治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病性胃不全麻痺治療の中南米市場規模2016-2027（メキシコ、ブラジル）...Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes. During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system. Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts...
  • 世界の糖尿病性胃不全麻痺治療薬市場規模・現状・予測2021-2027
    QY21APR1832 / QYResearch / 2021年4月 / 本調査資料では、糖尿病性胃不全麻痺治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、手術治療製品）、用途別市場規模（病院薬局、民間クリニック、ドラッグストア、Eコマース）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病性胃不全麻痺治療薬の市場動向 ・企業の競争状況、市場シェア ・糖尿病性胃不全麻痺治療薬の種類別市場規模（医薬品、手術治療製品） ・糖尿病性胃不全麻痺治療薬の用途別市場規模（病院薬局、民間クリニック、ドラッグストア、Eコマース） ・糖尿病性胃不全麻痺治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病性胃不全麻痺治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病性胃不全麻痺治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病性胃不全麻痺治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）...Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes. Market Analysis and Insights: Global Diabetic Gastroparesis Treatment Products Market The global Diabetic Gastroparesis Treatment Products market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Gastroparesis Treatment Products market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market...
  • 世界の糖尿病黄斑浮腫治療市場規模・現状・予測2021-2027
    QY21APR1834 / QYResearch / 2021年4月 / 本調査資料では、糖尿病黄斑浮腫治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（レーザー光凝固療法、薬物療法、ベバシズマブ、ラニビズマブ、トリアムシノロン）、用途別市場規模（病院、眼科クリニック、研究所、委託研究機関）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病黄斑浮腫治療の市場動向 ・企業の競争状況、市場シェア ・糖尿病黄斑浮腫治療の種類別市場規模（レーザー光凝固療法、薬物療法、ベバシズマブ、ラニビズマブ、トリアムシノロン） ・糖尿病黄斑浮腫治療の用途別市場規模（病院、眼科クリニック、研究所、委託研究機関） ・糖尿病黄斑浮腫治療の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病黄斑浮腫治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病黄斑浮腫治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病黄斑浮腫治療の中南米市場規模2016-2027（メキシコ、ブラジル）...Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by leakage of plasma constituents into the surrounding, consequently leading to edema. Increasing prevalence of diabetes in the prime factor driving growth of global diabetic macular edema therapeutics market. The prevalence of diabetic macular edema is higher in type 2 diabetes patients than in type 1 diabetes patients. As per study conducted by University Hospital Sant Joan de Reus Spain, the incidence of diabetic macular edema is in the range of 0.9%-2.3%, annually, across the globe....
  • 世界の糖尿病黄斑浮腫治療薬市場規模・現状・予測2021-2027
    QY21APR1833 / QYResearch / 2021年4月 / 本調査資料では、糖尿病黄斑浮腫治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（硝子体内注射、硝子体内インプラント）、用途別市場規模（抗VEGF、コルチコステロイド、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・糖尿病黄斑浮腫治療薬の市場動向 ・企業の競争状況、市場シェア ・糖尿病黄斑浮腫治療薬の種類別市場規模（硝子体内注射、硝子体内インプラント） ・糖尿病黄斑浮腫治療薬の用途別市場規模（抗VEGF、コルチコステロイド、その他） ・糖尿病黄斑浮腫治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病黄斑浮腫治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病黄斑浮腫治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病黄斑浮腫治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）...Market Analysis and Insights: Global Diabetic Macular Edema Drug Market The global Diabetic Macular Edema Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Macular Edema Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Macular Edema...

    • ◆H&Iグローバルリサーチのお客様（例）◆